Loading...
•
Dec 31, 2019
Bridgebio Q4 2019 Earnings Report
BridgeBio reported fourth quarter and full year 2019 financial results, highlighting pipeline progress and expansion.
Key Takeaways
BridgeBio Pharma reported its Q4 and full year 2019 financial results, showcasing pipeline expansion with the addition of five new drug development programs. The company ended the quarter with $577.1 million in cash, cash equivalents, and marketable securities.
Achieved multiple clinical and pre-clinical milestones across BridgeBio’s pipeline.
Expanded pipeline with five new drug development and discovery programs, bringing the total to over 20 potential medicines.
Initiated a rolling submission of an NDA with the United States FDA for Fosdenopterin for the treatment of patients with molybdenum cofactor deficiency (MoCD) type A.
Ended the quarter with $577.1 million in cash, cash equivalents and marketable securities.
Bridgebio
Bridgebio
Bridgebio Revenue by Segment
Revenue by Segment
License Revenue
CapyFin.com Forward Guidance
BridgeBio anticipates several milestones in 2020, including disclosing new product candidates, filing multiple INDs, sharing topline data from the BBP-589 Phase 1/2 study, and completing enrollment in the Phase 3 study of BBP-265 in ATTR-CM.
Positive Outlook
- Anticipate disclosing additional new product candidates and filing multiple new INDs in 2020
- Plan to share topline data from the ongoing Phase 1/2 study (NCT03752905) in 2020 for BBP-589.
- Anticipate dosing of first child in Phase 2 dose-ranging study (PROPEL2) in the coming months for Low-dose infigratinib.
- On track to complete enrollment in the Phase 3 study of AG10 in ATTR-CM in 2H20 (ATTRibute-CM).
- A Phase 3 study of AG10 in ATTR-PN (ATTRibute-PN) is on track to begin in 1H20.